Since the 2017 FDA approval of tisagenlecleucel® (first-in-class CD19-CAR T cell therapy for refractory acute lymphoblastic leukemia) (11), six CD19-CAR T cell products have been licensed for the treatment of B-cell malignancies and plasma cell dyscrasias (12, 13). The gene discussed is CD19; the disease is plasma cell neoplasm.